Cadranel S, Zeghlache S, Fernandez S, Safary A, André F
Clinique Pédiatrique, Hôpital Universitaire Saint Pierre, Université Libre de Bruxelles, Belgium.
Postgrad Med J. 1987;63 Suppl 2(736):159-60.
Thirty neonates born to HBsAg-positive mothers were vaccinated with a 20 microgram dose of the SmithKline Biologicals recombinant DNA yeast-derived vaccine within 24 hours after birth, with similar inoculations repeated 1 and 2 months later. Preliminary results indicate that the recombinant vaccine was well tolerated and immunogenic. A 100% seroconversion rate was achieved 4 months after the first vaccine dose and the anti-HBs geometric mean titres progressively rose from 14 to 31,279 and 361 IU/l at months 1, 2, 4, and 6, respectively. Although a longer period of observation and comparison with a historical control group are needed to evaluate its protective efficacy in this high-risk population, the fact that no vaccinated newborns have been infected is encouraging.
30名母亲为乙肝表面抗原（HBsAg）阳性的新生儿在出生后24小时内接种了20微克剂量的史克必成公司生产的重组DNA酵母源疫苗，在1个月和2个月后重复进行类似接种。初步结果表明，该重组疫苗耐受性良好且具有免疫原性。首次接种疫苗4个月后血清转化率达到100%，抗-HBs几何平均滴度在第1、2、4和6个月时分别从14 IU/l逐步升至31279 IU/l和361 IU/l。虽然需要更长时间的观察并与历史对照组进行比较，以评估其在这一高危人群中的保护效果，但尚无接种疫苗的新生儿被感染这一事实令人鼓舞。
